Boston Scientific has been cut nearly in half from its 52-week high after management delivered a guidance cut it openly called "sharp" and "unexpected" — and three of the best-capitalized device makers on earth are now converging on the exact two franchises, WATCHMAN and pulsed-field ablation, that were supposed to carry its growth through 2030. We ran the valuation four…
Boston Scientific Corporation (BSX) Equity Research Report – August 2026
This report is for members
The full analysis — model, valuation, scenarios and risks — plus the downloadable PDF, come with a Standard or Full membership.